Logo-aim
Arch Iran Med. 2021;24(2): 139-143. doi: 10.34172/aim.2021.22

Original Article

Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit

Mohsen Farrokhpour 1, Nader Rezaie 1, Najmeh Moradi 1, Fatemeh Ghaffari Rad 1, Shirin Izadi 1, Mehdi Azimi 1, Farhad Zamani 2, Shahrokh Izadi 3, Mitra Ranjbar 4, Mahin Jamshidi Makiani 4, Azadeh laali 5, Maryam Roham 4, Mahdi Yadollahzadeh 1 * ORCID

Cited by CrossRef: 21

1- Li H, He X, Zhang L, Li C, Li S, Li Q. Therapeutic Agents Rounding Up the Immunopathology of COVID-19. TCRM. 2021;Volume 17:657 [Crossref]
2- Marcec R, Dodig V, Radanovic I, Likic R. Intravenous immunoglobulin (IVIg) therapy in hospitalised adult COVID‐19 patients: A systematic review and meta‐analysis. Reviews in Medical Virology. 2022;32(6) [Crossref]
3- Yadollahzadeh M, Nasiripour S, Moradi Shahrbabak N, Rezaie N, Farrokhpour M, Azimi M, Izadi S, Zamani F, Farasatinasab M, Diba H. Colchicine with Infliximab Compared to Infliximab in Hospitalized Patients with COVID-19 Pneumonia: An Open-label Randomized Trial. COVID. 2024;5(1) [Crossref]
4- Ajmi H, Besghaier W, Kallala W, Trabelsi A, Abroug S. A fatal toxic shock-like syndrome post COVID-19 infection in a child. Ital J Pediatr. 2021;47(1) [Crossref]
5- Liu X, Zhang Y, Lu L, Li X, Wu Y, Yang Y, Li T, Cao W. Benefits of high-dose intravenous immunoglobulin on mortality in patients with severe COVID-19: An updated systematic review and meta-analysis. Front Immunol. 2023;14 [Crossref]
6- Amani B, Zareei S, Amani B, Zareei M, Zareei N, Shabestan R, Akbarzadeh A. Artesunate, imatinib, and infliximab in COVID‐19: A rapid review and meta‐analysis of current evidence. Immunity Inflam & Disease. 2022;10(6) [Crossref]
7- Aliyu B, Raji Y, Chee H, Wong M, Sekawi Z, Abd El-Aty A. Systematic review and meta-analysis of the efficacy and safety of oseltamivir (Tamiflu) in the treatment of Coronavirus Disease 2019 (COVID-19). PLoS ONE. 2022;17(12):e0277206 [Crossref]
8- Saied Y, Abou Warda A, Allam R, Syed W, Basil A. Al-Rawi M, Iqbal A, Elgendy M, M. El-Sabaa R, Hassan A. The Impact of Infliximab on Hyperinflammation State in Hospitalized COVID-19 Patients: A Retrospective Study. Medicina. 2024;60(10):1670 [Crossref]
9- Farahani M, Niknam Z, Mohammadi Amirabad L, Amiri-Dashatan N, Koushki M, Nemati M, Danesh Pouya F, Rezaei-Tavirani M, Rasmi Y, Tayebi L. Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets. Biomedicine & Pharmacotherapy. 2022;145:112420 [Crossref]
10- Salehi M, Barkhori Mehni M, Akbarian M, Fattah Ghazi S, Khajavi Rad N, Moradi Moghaddam O, Jamali Moghaddam S, Hosseinzadeh Emam M, Abtahi S, Moradi M, Ghiasvand F. The outcome of using intravenous immunoglobulin (IVIG) in critically ill COVID-19 patients’: a retrospective, multi-centric cohort study. Eur J Med Res. 2022;27(1) [Crossref]
11- Moura A, Lopes L, Matos L, Machado J, Criado M. Converging Paths: A Comprehensive Review of the Synergistic Approach between Complementary Medicines and Western Medicine in Addressing COVID-19 in 2020. BioMed. 2023;3(2):282 [Crossref]
12- Fatemi B, Rezaei S, Peikanpour M, Dastan F, Saffaei A. Efficacy of intravenous immunoglobulins (IVIG) in COVID-19 patients: a systematic review and meta-analysis. 2023;18(4):346 [Crossref]
13- Rommasi F, Nasiri M, Mirsaeidi M. Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features. Mol Cell Biochem. 2022;477(3):711 [Crossref]
14- Farjami A, Montazersaheb S, Soofiyani S, Akbarzadehlaleh P, Salatin S. Biopharmaceuticals for prevention of COVID-19. 2022;15(6):245 [Crossref]
15- Bustamante S, Yau Y, Boys V, Chang J, Paramsothy S, Pudipeddi A, Leong R, Wasinger V. Tryptophan Metabolism ‘Hub’ Gene Expression Associates with Increased Inflammation and Severe Disease Outcomes in COVID-19 Infection and Inflammatory Bowel Disease. IJMS. 2022;23(23):14776 [Crossref]
16- Kokkotis G, Kitsou K, Xynogalas I, Spoulou V, Magiorkinis G, Trontzas I, Trontzas P, Poulakou G, Syrigos K, Bamias G. Systematic review with meta‐analysis: COVID‐19 outcomes in patients receiving anti‐TNF treatments. Aliment Pharmacol Ther. 2022;55(2):154 [Crossref]
17- Abdoli A, Falahi S, Kenarkoohi A. COVID-19-associated opportunistic infections: a snapshot on the current reports. Clin Exp Med. 2021;22(3):327 [Crossref]
18- Pehlivan Ö, Aydin T. Clinical outcomes of patients with COVID-19 and inflammatory rheumatic diseases receiving biological/targeted therapy. Ann Saudi Med. 2022;42(3):155 [Crossref]
19- Li M, Li Y, Xing X, Niu J, Yao L, Lu M, Guo K, Ma M, Wu X, Ma N, Li D, Li Z, Guan L, Wang X, Pan B, Shang W, Ji J, Song Z, Zhang Z, Wang Y, Yang K. Intravenous immunoglobulin for treatment of hospitalized COVID-19 patients: an evidence mapping and meta-analysis. Inflammopharmacol. 2023; [Crossref]
20- Sameni M, Mirmotalebisohi S, Dadashkhan S, Ghani S, Abbasi M, Noori E, Zali H. COVID-19: A novel holistic systems biology approach to predict its molecular mechanisms (in vitro) and repurpose drugs. DARU J Pharm Sci. 2023;31(2):155 [Crossref]
21- Velez M, McCarthy M. Infliximab as a potential treatment for COVID-19. Expert Review of Anti-infective Therapy. 2023;21(1):1 [Crossref]
22- Chen Y, Xie J, Wu W, Li S, Hu Y, Hu M, Li J, Yang Y, Huang T, Zheng K, Wang Y, Kang H, Huang Y, Jiang L, Zhang W, Zhong M, Sang L, Zheng X, Pan C, Zheng R, Li X, Tong Z, Qiu H, Weng L, Du B. Intravenous Immunoglobulin Therapy for Critically Ill COVID-19 Patients With Different Inflammatory Phenotypes: A Multicenter, Retrospective Study. Front Immunol. 2022;12 [Crossref]

SCImago Journal & Country Rank

About Us

A Monthly Peer-Reviewed Medical Journal Published by the Academy of Medical Sciences of the I.R. Iran; Indexed in PubMed/MEDLINE, ISI Web of Science, EMBASE, SCOPUS, CINHAL, PASCAL, CSA, SID, ISSN: Print 1029-2977, Online 1735-3947.The impact factor of Archives of Iranian Medicine according to Journal Citation Reports® (JCR®) 2016 is 1.20.